| DC11053 |
GAK inhibitor 49
Featured
|
GAK inhibitor 49 is a potent, selective, ATP-competitive inhibitor of cyclin G-associated kinase (GAK, cell IC50=56 nM) with favourable NAK family selectivity (AAK1, STK16, BMP2K). |
|
| DC12228 |
Galactose 1-phosphate |
Galactose 1-phosphate is an intermediate in the galactose metabolism and nucleotide sugars. |
|
| DC12305 |
Galactose 1-phosphate Potassium salt |
Galactose 1-phosphate Potassium salt is is an intermediate in the galactose metabolism and nucleotide sugars |
|
| DC21038 |
Galvestine-1 |
Galvestine-1 is a small molecule MGDG (monogalactosyldiacylglycerol) synthase inhibitor with IC50 of 10 uM by competing with diacylglycerol binding. |
|
| DC11071 |
Gambogenic acid |
Gambogenic acid (GNA) is a polyprenylated xanthone isolated from gamboge, shows potent antitumor activity and can effectively inhibit the survival and proliferation of cancer cells. |
|
| DC12090 |
Gamitrinib TPP |
Gamitrinib TPP is a GA mitochondrial matrix inhibitor. |
|
| DC9640 |
gamma-secretase modulator 3 |
gamma-secretase modulator 3 is a gamma-secretase modulator. |
|
| DC21197 |
Ganaplacide
Featured
|
Ganaplacide (KAF156, GNF-156) is a novel antimalarial clinical candidate that shows blood schizonticidal activity with IC50 of 6-17.4 nM against P falciparum drug-sensitive and drug-resistant strains. |
|
| DC9453 |
GANT 58 |
GANT 58 is a novel and potent Gli antagonist that inhibits GLI1-induced transcription (IC50 = 5 uM). |
|
| DC20388 |
GAPDS
Featured
|
GAPDS is a small molecule that targets the glycolytic enzyme glyceraldehyde 3-phosphate dehydrogenase (GAPDH). |
|
| DC23398 |
Garcinol |
Garcinol (Camboginol) is a potent, natural inhibitor of histone acetyltransferases (HATs) p300 (IC50=7 uM) and PCAF (IC50=5 uM) both in vitro and in vivo. |
|
| DC8929 |
Garenoxacin |
Garenoxacin is a quinolone antibiotic for the treatment of Gram-positive and Gram-negative bacterial infections. |
|
| DC8893 |
Garenoxacin Mesylate hydrate |
Garenoxacin mesylate hydrate is a novel oral des-fluoro(6) quinolone with potent antimicrobial activity, against common respiratory pathogens, including resistant strains. |
|
| DC11122 |
GAT-100 |
GAT-100 (GAT100) is a potent, selective CB1R negative allosteric modulator (NAM) with cAMP EC50 and β-arr EC50 of 174 nM and 2.1 nM, does not exhibit inverse agonism. |
|
| DC11119 |
GAT-211 |
GAT-211 (GAT211) is a selective cannabinoid 1 receptor (CB1R) positive allosteric modulator with pKb of 7.26, Arrestin2 EC50 of 775 nM. |
|
| DC11741 |
GB-110 |
GB-110 is a potent, non-peptidic agonist of PAR2 that selectively induces PAR2-mediated intracellular Ca(2+) release in HT29 cells with EC50 of 0.28 uM. |
|
| DC22098 |
GB1107 |
GB1107 (GB-1107, GB 1107) is a potent, selective, orally active inhibitor of Galectin-3 (Gal-3) with Kd of 37 nM (human Galectin-3). |
|
| DC21040 |
GB-83 |
GB-83 is a selective, reversible PAR2 (Protease-activated receptor 2) antagonist with IC50 of 2 uM. |
|
| DC11740 |
GB-88 |
GB-88 is a selective, orally available PAR2 antagonist that inhibits PAR2 activated Ca(2+) release with IC50 of 2 uM. |
|
| DC10153 |
GDC-0077
Featured
|
GDC-0077 is an orally available PI3K inhibitor with potential antineoplastic activity. GDC-0077 is extracted from patent WO 2017001645 A1, formula I. |
|
| DC10035 |
GDC-0326 |
GDC-0326 is a potent and selective inhibitor of α-Isoform of Phosphoinositide 3-Kinase (PI3Kalpha inhibitor). |
|
| DC8216 |
GDC-0349 |
GDC-0349 is a potent and selective ATP-competitive inhibitor of mTOR with Ki of 3.8 nM; >700-fold selectivity over PI3Kα and other 266 kinases. |
|
| DC8519 |
GDC046
Featured
|
GDC046 is a potent lead analog with good kinase selectivity, physicochemical properties, and pharmacokinetic profile. |
|
| DC8000 |
GDC-0623
Featured
|
GDC-0623 is a potent, ATP-uncompetitive inhibitors of MEK1(Ki=0.13 nM, +ATP). |
|
| DC9942 |
GDC-0853(RG7845)
Featured
|
GDC-0853 is orally available inhibitor of Bruton's tyrosine kinase (BTK) with potential antineoplastic activity. |
|
| DC23714 |
GDC-0927 R-form |
GDC-0927 (SRN-927, RG-6047) is a potent, orally bioavailable, selective estrogen receptor degrader (SERD) for treatment of metastatic hormone receptor-positive/HER2-negative breast cancer.. |
|
| DC23717 |
GDC-0927 |
GDC-0927 (SRN-927, RG-6047) is a potent, orally bioavailable, selective estrogen receptor degrader (SERD) for treatment of metastatic hormone receptor-positive/HER2-negative breast cancer.. |
|
| DC12062 |
GDC-0927 Racemate |
GDC-0927 Racemate is a degrader of estrogen receptor, potently inhibits ER-α activity, with an IC50 of 0.2 nM, and is used in the research of ER-related diseases. |
|
| DC9592 |
GDC-0941 (dimethanesulfonate) |
GDC-0941 2 MeSO3H salt is a potent inhibitor of PI3Kα/δ with IC50 of 3 nM, with modest selectivity against p110β (11-fold) and p110γ (25-fold).
|
|
| DC7766 |
Ravoxertinib
Featured
|
GDC-0994 is a potent, orally available ERK1/2 inhibitor with IC50 of 1.1 nM and 0.3 nM, respectively. Phase 1. |
|
